Clinical Trial Search

Primary: Percentage of Participants Who Required Study Drug Dose Reduction During Treatment Periods 1 and 2 — 4.5; 0.0 percentage of participants

Primary: Total Radioactivity in Plasma Following Administration of [14C]-AZD2014 — 4013; 3415; 2901; 2693 nanogram equivalent/millilitre (ngEq/mL)

Primary: Number of Participants Who Experienced Adverse Events — 30; 31 Participants

Primary: Percentage of Participants With Plasma Human Immunodeficiency Virus Type 1 (HIV-1) Ribonucleic Acid (RNA) <50 Copies/mL (c/mL) at Week 48 — 93; 94 Percentage of…

Primary: Change From Baseline in Mean Intraocular Pressure (IOP) in the Study Eye to Month 12 — 21.7; 21.0; -6.6; -6.4 mmHg

Primary: Global Tidal Variation (TID) — 100; 100; 101.7; 109.1 percentage of baseline — p=0.26

Primary: Number of Participants With Immediate Reactions — 0; 0; 0; 0 Participants

Primary: PROMIS Asthma Impact Scale (v1.0, SF8a) — -7.8; -9.3; -11.9 T-score

Primary: The Primary Efficacy Objective of This Study is to Assess the Efficacy of SYN120 on Cognition as Determined by the Cognitive Drug Research Computerized Cognition Battery…

Primary: Lag Time (Tlag) of Ridaforolimus: Day 1 — 2.00 Hours

Primary: Peak Levels of Interferon Gamma-induced Protein 10 (IP-10) in Nasal Wash Fluid — 2000; 1900 pg/mL

Primary: Arithmetic Mean of Individual Sun Protection Factor (SPFi) Value — 19.4; 14.0 Ratio (unit less)

Primary: Number of Children With Health Insurance — 117; 78; 6; 36 Participants

Primary: Number of Participants With Solicited Adverse Events (Local & Systemic Reactogenicity) — 5; 1; 5; 0 Participants

Primary: Percentage of Participants Who Successfully Performed Safety-Critical and Essential Tasks During First Unassisted Use — 100.00; 100.00; 100.00; 100.00 percentage of…